echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > EPO market broke out under domestic monopoly or exceeded 10 billion!

    EPO market broke out under domestic monopoly or exceeded 10 billion!

    • Last Update: 2017-09-13
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Source: pharmaceutical economic report 2017-09-13 erythropoietin (hereinafter referred to as EPO) is the abbreviation of "erythropoietin", which is a kind of glycoprotein physiological substance synthesized by the kidney Its main function is to promote the bone marrow to produce more red cells At first, Amgen bioengineering company of the United States first developed it into a drug for marketing with the help of genetic engineering technology, which is mainly used for the treatment of malignant anemia, especially for anemia symptoms caused by long-term renal failure patients In the next few years, foreign medical researchers have found that EPO has a good effect on AIDS patients, chemotherapy patients and other special patients For a long time, the international EPO market has been monopolized by the products of four major companies, including Hoffman Roche (Switzerland), Amgen (US), Johnson & Johnson (US) and kylin co fermentation (Japan) The total EPO sales of the above four companies account for more than 80% of the international EPO market, while the total sales of dozens of EPO manufacturers in other countries and regions account for more than 10% of the rest EPO is also a biomedical product with an amazing growth rate Its annual global sales in 1990, shortly after its launch, were only $200 million But 15 years later, the total global sales of EPO, which was not favored by the industry at the beginning, reached 11.9 billion US dollars in 2004, and its sales increased 60 times in just 15 years! EPO has thus become the first bioengineering drug in the world with sales exceeding 10 billion US dollars Even by 2014, EPO was still in the top 10 of the world's top 100 best-selling drugs Although the drug lost patent protection a few years ago, its annual sales remained around 10 billion US dollars, which shows that the product has a very strong market vitality and created a myth that bioengineering drugs are not old With the two EPO brand products in the international market, epoetin - α and darbeoetin - α patents expired several years ago, the world has set off a climax of imitating EPO biological analogues In the early 1990s, China's scientific research institutions began to develop EPO The first two experts who were successful and put into the commercial production of EPO were two experts from Nanjing Naval Medical College, and Nanjing Huaxin bioengineering company was founded to specialize in the production of protein / peptide drugs such as EPO At that time, the price of domestic EPO was only 30-40% of the price of imported similar products, so the domestic EPO market has grown rapidly in the past few years, among which Shenyang Sansheng company, Shandong Kexing company and Jintan biological company under North China Pharmaceutical Group have become the "leader" in the domestic EPO industry Nanjing Huaxin company, which first developed the product, now ranks 10th in the domestic EPO market, which shows the cruelty of the market competition In the domestic EPO industry, the latecomers are mainly Shenzhen Kexing company and Shenyang Sansheng pharmaceutical company, but the main products of Sansheng company are a series of bioengineering drugs in addition to EPO By the beginning of the 21st century, Shenyang Sansheng company's EPO products have firmly occupied more than 30% of the domestic market, with an annual output of 10 million In recent years, Shenyang Sansheng company's EPO products have begun to be exported to overseas markets, including Indonesia, Ukraine, Pakistan and other South Asian countries Shanghai Kirin (Kunpeng) Pharmaceutical Co., Ltd is a Sino Japanese joint venture pharmaceutical enterprise It introduces Japanese technology to produce recombinant gene person EPO products In 2012, the company was renamed Shanghai Xiehe Pharmaceutical Co., Ltd and the products are still bioengineering drugs such as EPO It is understood that the EPO of Shanghai Xiehe company accounts for about 2% of the domestic market, and some products are also sold back to the Japanese market Due to the high profit rate of EPO, many domestic enterprises have joined in the production By the end of 2010, more than 20 domestic companies have obtained the production approval of national EPO, but only 11 companies actually produce EPO According to preliminary estimates of relevant departments, at present, the total capacity of domestic EPO has exceeded 1 billion, which can basically meet the domestic market demand Several major EPO producers, such as Shenyang Sansheng, Shandong Kexing, Huabei pharmaceutical and Shanghai Xiehe, have the strength to enter the overseas market Jintan bio, a subsidiary of Huabei Pharmaceutical Group, has about 10% of the domestic market in terms of EPO output Several foreign brands that once monopolized the Chinese EPO market in the 1990s withdrew from the Chinese market due to the centralized listing of EPOS of several local companies Domestic EPO products have gradually squeezed out the share of foreign brands such as the United States and Germany in China's EPO market due to their competitive advantages of high quality and low price In 2006, the market share of domestic EPO and imported EPO was 7:3 Last year, the proportion of foreign-funded EPO products in the domestic market was less than 10% Chinese EPO products have fully established their foothold in the domestic market, while foreign-funded enterprises' products have obviously "lost" in China This shows that China's bioengineering pharmaceutical industry has begun to grow and grow As the domestic market of EPO is promising, many listed companies have entered into the production field of EPO products with their abundant capital For example, Shenzhen Petrochemical, Fuxing industry and Shandong dong'a company all invested in the original EPO company or newly established company to engage in EPO production For example, the new EPO production line of Jintan biological company, funded by Huabei Pharmaceutical Group, has been put into production successfully and has become the main force in the domestic EPO industry Shenyang Sansheng company, the earliest producer of EPO in China, with its excellent engineering and technical team, announced to reduce the price of all specifications of EPO preparations by about 30% two years ago, so as to defeat other domestic EPO producers Shenyang Sansheng's price reduction really has a greater "lethality" to the small EPO manufacturers with insufficient domestic strength, so some companies have dropped out of the EPO production ranks and changed to other products As a result, Shenyang Sansheng became the top producer of EPO in China After a reshuffle of EPO industry, the products of Shenyang Sansheng company have accounted for about 70% of the domestic market Strong export growth momentum in the past three years, China's EPO exports have made major breakthroughs From only tens of thousands of EPOS per year in the 1990s to millions of EPOS last year, the main export destinations have been expanded to dozens of countries In addition to Eastern European countries such as Ukraine, there are also South Asian countries such as Pakistan, Middle East Arab countries such as Uzbekistan and Egypt, West African countries and Southeast Asian countries According to the statistics of China Chamber of Commerce for the import and export of medical and health care products, China's export of EPO in 2011 increased by 11% over the previous year, while in 2012 it increased by 48% over the previous year The export growth momentum of domestic EPO is very strong, indicating that the quality of domestic EPO has been recognized by the international community According to the analysis, China's export price of EPO is only about 40% of the same kind of Western products on average, so it has a strong competitiveness in the international market Due to the fierce competition in the domestic market, the main domestic EPO manufacturers are looking to the overseas market In a word, China's EPO products have already gone abroad to the world After the market reshuffle in the past few years, only 11 domestic companies are still producing EPO products, among which the total EPO production capacity of 3 or 4 companies with large production accounts for about 80 or 90% of the total domestic EPO production capacity, and that of other companies only accounts for more than 10% of the rest In 2015, the global EPO market showed an overall upward trend Because more and more countries regard EPO as the first choice of drugs to treat renal failure anemia, it becomes the primary factor to ensure the strong growth of EPO international market For example, India's EPO market has developed rapidly in the past few years In 2001, the total sales volume of India's EPO market was 3.52 billion rupees, compared with 7.5 billion rupees in 2011 Last year, it was closer to 9 billion rupees, with an amazing growth rate According to the analysis, the main reason for the rapid growth of India's EPO market is the same as that of China, that is to say, India's domestic enterprises have made major breakthroughs in EPO technology, thus breaking the monopoly of foreign companies in India's EPO market At present, the price of domestic EPO preparations in India is only 1 / 10 ~ 1 / 8 of that of similar products of foreign companies Western market analysts believe that India, like China, will soon become an important force in the international EPO market After India, emerging industrial countries such as Brazil and Russia will also become new hot spots for the growth of international EPO market Datamonitor, a European consulting firm, forecasts that the sales of EPO markets in four major BRICs countries, including China, India, Pakistan and Russia, will reach the targets of 416 million US dollars, 228 million US dollars, 205 million US dollars and 100 million US dollars respectively this year How to improve the market prospect of EPO by medical insurance payment is one of the most concerned issues in the industry According to statistics from China Chamber of Commerce for the import and export of medical and health products, the sales volume of EPO market in China has exceeded 2 billion yuan for the first time last year Many provinces have already included EPO in the scope of medical insurance reimbursement drugs, and it is expected that EPO will be included in the scope of medical insurance reimbursement in most provinces and cities in the future Once China 's EPO can be included in the list of drugs for universal medical insurance reimbursement like western developed countries, people in the health sector expect that the total sales of China' s EPO will easily jump to the level of 10 billion yuan Although the drug has been reduced for many times, it is still not cheap, and each drug still needs more than 100 yuan If the price can be further reduced, the total sales volume of domestic EPO will definitely increase substantially According to the report from the health department, there are nearly 7 million patients with renal failure in China They are potential users of EPO In addition, the patients with malignant tumor who receive chemotherapy will become the main users of EPO If China can reach the level of use of EPO in developed countries, then China's EPO market will eventually exceed 10 billion yuan or higher.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.